Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HeartSciences Inc.HSCS · Entity 7830 | Director | December 22, 2025 | December 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HeartSciences Inc.
Report date December 22, 2025 · Filed December 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 15,000 |
Reported balance
After 2025-12-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-22 · Grant · Acquired 15,000 · Balance 15,000 F1: Represents Restricted Stock Units (the "RSUs") granted to the Reporting Person under the Issuer's 2023 Equity Incentive Plan (as amended, the "Plan") pursuant to the approval of the Issuer's board of directors. Each vested RSU shall be settled by delivery to the Reporting Person of one share of the Issuer's common stock, $0.001 par value per share, upon satisfaction of the Conditions (as defined below). F2: The RSUs shall vest subject to the satisfaction of all of the following conditions (the "Conditions"): (i) approval by the Issuer's shareholders of any amendment or modification to or restatement of the Plan, which, among other things, contemplates the award of the RSUs; and (ii) (x) 1/2 of the RSUs shall vest on the one-year anniversary of the grant date (the "Initial Vesting Date") and (y) thereafter, 1/8th of the RSUs shall vest on each subsequent quarterly anniversary of the Initial Vesting Date (each an "Additional Initial Vesting Date" and together with the Initial Vesting Date, the "Vesting Dates"), such that all of the RSUs shall fully vest on the two-year anniversary of the grant date in each case provided that the Reporting Person is continuously serving on the Board through each applicable Vesting Date. F3: 100% of the RSUs shall vest (i) in the event of a Change of Control (as defined in the Plan) or (ii) if the Issuer achieves $250,000 or more of revenue in any fiscal quarter ending after the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units (the "RSUs") granted to the Reporting Person under the Issuer's 2023 Equity Incentive Plan (as amended, the "Plan") pursuant to the approval of the Issuer's board of directors. Each vested RSU shall be settled by delivery to the Reporting Person of one share of the Issuer's common stock, $0.001 par value per share, upon satisfaction of the Conditions (as defined below).
F2: The RSUs shall vest subject to the satisfaction of all of the following conditions (the "Conditions"): (i) approval by the Issuer's shareholders of any amendment or modification to or restatement of the Plan, which, among other things, contemplates the award of the RSUs; and (ii) (x) 1/2 of the RSUs shall vest on the one-year anniversary of the grant date (the "Initial Vesting Date") and (y) thereafter, 1/8th of the RSUs shall vest on each subsequent quarterly anniversary of the Initial Vesting Date (each an "Additional Initial Vesting Date" and together with the Initial Vesting Date, the "Vesting Dates"), such that all of the RSUs shall fully vest on the two-year anniversary of the grant date in each case provided that the Reporting Person is continuously serving on the Board through each applicable Vesting Date.
F3: 100% of the RSUs shall vest (i) in the event of a Change of Control (as defined in the Plan) or (ii) if the Issuer achieves $250,000 or more of revenue in any fiscal quarter ending after the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2025 Filed Dec 22, 2025 23:39 UTC | HeartSciences Inc. HSCS · Entity 7830 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-124719 · ownership.xml · derivative · entry 1 Szymczak Brian · CIK 0001933355 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Represents Restricted Stock Units (the "RSUs") granted to the Reporting Person under the Issuer's 2023 Equity Incentive Plan (as amended, the "Plan") pursuant to the approval of the Issuer's board of directors. Each vested RSU shall be settled by delivery to the Reporting Person of one share of the Issuer's common stock, $0.001 par value per share, upon satisfaction of the Conditions (as defined below). F2 · derivative.exercise_date: The RSUs shall vest subject to the satisfaction of all of the following conditions (the "Conditions"): (i) approval by the Issuer's shareholders of any amendment or modification to or restatement of the Plan, which, among other things, contemplates the award of the RSUs; and (ii) (x) 1/2 of the RSUs shall vest on the one-year anniversary of the grant date (the "Initial Vesting Date") and (y) thereafter, 1/8th of the RSUs shall vest on each subsequent quarterly anniversary of the Initial Vesting Date (each an "Additional Initial Vesting Date" and together with the Initial Vesting Date, the "Vesting Dates"), such that all of the RSUs shall fully vest on the two-year anniversary of the grant date in each case provided that the Reporting Person is continuously serving on the Board through each applicable Vesting Date. F3 · derivative.exercise_date: 100% of the RSUs shall vest (i) in the event of a Change of Control (as defined in the Plan) or (ii) if the Issuer achieves $250,000 or more of revenue in any fiscal quarter ending after the date hereof. F2 · derivative.expiration_date: The RSUs shall vest subject to the satisfaction of all of the following conditions (the "Conditions"): (i) approval by the Issuer's shareholders of any amendment or modification to or restatement of the Plan, which, among other things, contemplates the award of the RSUs; and (ii) (x) 1/2 of the RSUs shall vest on the one-year anniversary of the grant date (the "Initial Vesting Date") and (y) thereafter, 1/8th of the RSUs shall vest on each subsequent quarterly anniversary of the Initial Vesting Date (each an "Additional Initial Vesting Date" and together with the Initial Vesting Date, the "Vesting Dates"), such that all of the RSUs shall fully vest on the two-year anniversary of the grant date in each case provided that the Reporting Person is continuously serving on the Board through each applicable Vesting Date. F3 · derivative.expiration_date: 100% of the RSUs shall vest (i) in the event of a Change of Control (as defined in the Plan) or (ii) if the Issuer achieves $250,000 or more of revenue in any fiscal quarter ending after the date hereof. Read SEC document |
| July 09, 2025 Filed Jul 12, 2025 01:00 UTC | HeartSciences Inc. HSCS · Entity 7830 | GrantStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $4.37 | Not disclosed |
DisclosureSEC source: 0001213900-25-063413 · ownership.xml · derivative · entry 1 Szymczak Brian · CIK 0001933355 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-07-09 F1 · derivative.exercise_price: These options were granted to the Reporting Person effective as of July 9, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors. F1 · price: These options were granted to the Reporting Person effective as of July 9, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors. F2 · derivative.exercise_date: The options shall vest and be exercisable as follows: one-fourth of the options vested on the Effective Date and the remainder of the options shall vest in equal increments thereafter on each successive three-month anniversary of the Effective Date, subject to the Reporting Person's continued service on the Board through each applicable vesting date and subject to the terms of the Issuer's 2023 Equity Incentive Plan, as amended (the "2023 Plan"). F3 · derivative.expiration_date: These options expire ten years from the Effective Date, unless terminated sooner in accordance with the Issuer's 2023 Plan or the underlying options grant agreement. Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 22:16 UTC | HeartSciences Inc. HSCS · Entity 7830 | GrantEmployee Stock Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $3.33 | Not disclosed |
DisclosureSEC source: 0001213900-25-005088 · ownership.xml · derivative · entry 1 Szymczak Brian · CIK 0001933355 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2035-01-16 F1 · derivative.exercise_price: These options were granted to the Reporting Person effective as of January 16, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors. F1 · price: These options were granted to the Reporting Person effective as of January 16, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors. F2 · derivative.exercise_date: The options shall vest and be exercisable as follows: one-fourth of the options vested on the Effective Date and the remainder of the options shall vest in equal increments thereafter on each successive three-month anniversary of the Effective Date, subject to the Reporting Person's continued service on the Board through each applicable vesting date and subject to the terms of the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"). F3 · derivative.expiration_date: These options expire ten years from the Effective Date, unless terminated sooner in accordance with the Issuer's 2023 Plan or the underlying options grant agreement. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 23:56 UTC | HeartSciences Inc. HSCS · Entity 7830 | GrantDirector Stock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $0.97 | Not disclosed |
DisclosureSEC source: 0000899243-23-009455 · doc4.xml · derivative · entry 1 Szymczak Brian · CIK 0001933355 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-03-20 F1 · derivative.exercise_price: These options were granted to the Reporting Person effective as of March 20, 2023 (the "Effective Date"), pursuant to the approval of the Issuer's board of directors (the "Board") on March 20, 2023. F1 · price: These options were granted to the Reporting Person effective as of March 20, 2023 (the "Effective Date"), pursuant to the approval of the Issuer's board of directors (the "Board") on March 20, 2023. F2 · derivative.exercise_date: The options shall vest in four equal increments, with the first tranche of the options vesting on June 20, 2023 (the "Initial Vesting Date"), with an additional one-fourth of the options vesting on each successive three-month anniversary of the Initial Vesting Date, subject to the Reporting Person's continued service on the Board through each applicable vesting date and subject to the terms of the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"). F3 · derivative.expiration_date: These options expire ten years from the Effective Date, unless terminated sooner in accordance with the 2023 Plan or the underlying options grant agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.